◆

Subtypes

3

SMARCB1-related Schwannomatosis MONDO:0024517

SMARCB1 hgnc:11103 {'name': 'Autosomal dominant'}

Schwannomatosis caused by a germline pathogenic variant in SMARCB1 (INI1/BAF47), a core subunit of the SWI/SNF chromatin-remodeling complex on chromosome 22q11. Accounts for roughly half of familial schwannomatosis. Carries an elevated risk of malignant peripheral nerve sheath tumor and of meningioma relative to LZTR1-related disease.

Show evidence (2 references)

PMID:29517885 SUPPORT Human Clinical

"Malignancy remains a risk especially in individuals with SMARCB1-related schwannomatosis."

GeneReviews notes the elevated malignancy risk in SMARCB1-related schwannomatosis.

PMID:24362817 SUPPORT Human Clinical

"Constitutional SMARCB1 mutations at 22q11.23 have been found in ∼50% of familial and <10% of sporadic schwannomatosis cases."

Quantifies the contribution of germline SMARCB1 mutations to familial and sporadic schwannomatosis.

LZTR1-related Schwannomatosis MONDO:0014299

LZTR1 hgnc:6742 {'name': 'Autosomal dominant'}

Schwannomatosis caused by a germline pathogenic variant in LZTR1, a CUL3 ubiquitin-ligase substrate adaptor on chromosome 22q11. Associated with multiple non-intradermal schwannomas and, unlike SMARCB1-related disease, a recognized risk of unilateral vestibular schwannoma.

Show evidence (1 reference)

PMID:24362817 SUPPORT Human Clinical

"Our findings identify LZTR1 as a gene predisposing to an autosomal dominant inherited disorder of multiple schwannomas in ∼80% of 22q-related schwannomatosis cases lacking mutation in SMARCB1."

Piotrowski 2014 is the primary LZTR1 discovery paper, identifying germline LZTR1 loss of function as the predisposing event in most SMARCB1-negative 22q-related schwannomatosis.

22q-related / Unknown-gene Schwannomatosis

Clinically diagnosed schwannomatosis in which no germline SMARCB1 or LZTR1 pathogenic variant is identified. A substantial proportion of patients — particularly sporadic cases — fall into this category, reflecting either undetected variants in known genes, mosaic NF2 disease detectable mainly by tumor testing, or as-yet-unidentified predisposition genes.

Show evidence (2 references)

PMID:39209702 SUPPORT Human Clinical

"19 people had an NF2 variant, but 18 of these were mosaic and 17 were only detected when 2 tumours were available for testing."

Documents that many schwannomatosis cases without a germline SMARCB1/LZTR1 variant are explained by mosaic NF2 detectable only on tumor testing.

PMID:39209702 SUPPORT Human Clinical

"The overall detection rate was 25% using blood alone, but increased to 36% when tumour analysis was included."

Supports that a large fraction of clinically diagnosed schwannomatosis lacks an identifiable germline variant on blood testing.

⚙

Pathophysiology

6

Germline SMARCB1 or LZTR1 Loss of Function (First Hit)

The predisposing event is a germline loss-of-function variant in SMARCB1 (a core SWI/SNF chromatin-remodeling subunit) or LZTR1 (a CUL3 ubiquitin-ligase substrate adaptor), both located on chromosome 22q. This heterozygous germline "first hit" sensitizes Schwann-cell precursors to subsequent somatic events that complete tumorigenesis.

Schwann cell CL:0002573

SMARCB1 hgnc:11103 LZTR1 hgnc:6742

Downstream

Composite 4-Hit/3-Event 22q Inactivation The germline first hit is followed by somatic loss of the other allele and biallelic NF2 inactivation.

SMARCB1 SWI/SNF Chromatin-Remodeling Dysfunction Germline SMARCB1 loss of function impairs SWI/SNF (BAF) chromatin-remodeling activity in Schwann-cell precursors.

LZTR1-CUL3 Substrate Adaptor Dysfunction Germline LZTR1 loss of function impairs CUL3-mediated substrate ubiquitination, dysregulating RAS-MAPK signaling.

Composite 4-Hit/3-Event 22q Inactivation

Schwannomas in SMARCB1/LZTR1-related schwannomatosis arise through a characteristic composite mechanism involving four mutational hits across three events: the germline first hit in SMARCB1 or LZTR1, somatic inactivation of the remaining wild-type SMARCB1/LZTR1 allele, and somatic biallelic inactivation of NF2. Because SMARCB1, LZTR1, and NF2 all lie on chromosome 22q, a single somatic loss of one 22q copy can simultaneously remove the remaining predisposition-gene allele and one NF2 allele, leaving a second somatic NF2 mutation to complete the process.

Schwann cell CL:0002573

NF2 hgnc:7773

negative regulation of cell population proliferation GO:0008285 ↓ DECREASED

Downstream

Merlin Loss and Schwann-Cell Tumorigenesis Biallelic NF2 inactivation eliminates merlin, the shared effector driving schwannoma growth.

Show evidence (3 references)

PMID:18072270 SUPPORT Human Clinical

"A novel germline SMARCB1 mutation was found in one patient; inactivating somatic mutations of NF2, associated with loss of heterozygosity (LOH) of 22q, were found in two schwannomas of this patient."

Documents the germline SMARCB1 first hit plus somatic NF2 inactivation with 22q LOH in schwannomatosis tumors.

PMID:18072270 SUPPORT Human Clinical

"a four-hit mechanism involving the SMARCB1 and NF2 genes may be implicated in schwannomatosis-related tumorigenesis"

Establishes the composite four-hit SMARCB1/NF2 mechanism underlying schwannomatosis tumorigenesis.

PMID:24362817 SUPPORT Human Clinical

"schwannomas involved somatic loss of one copy of 22q, encompassing SMARCB1 and NF2, with a different somatic mutation of the other NF2 allele in every schwannoma"

Documents the 22q loss co-removing the predisposition gene and one NF2 allele plus a second somatic NF2 mutation, the core of the 4-hit/3-event mechanism.

SMARCB1 SWI/SNF Chromatin-Remodeling Dysfunction

SMARCB1 (INI1/BAF47) is a core subunit of the SWI/SNF (BAF) ATP-dependent chromatin-remodeling complex. Loss of SMARCB1 impairs SWI/SNF-mediated nucleosome remodeling and gene regulation, contributing to Schwann-cell transformation and underlying the higher malignancy risk in SMARCB1-related disease (epithelioid morphology with INI1 loss).

Schwann cell CL:0002573

SMARCB1 hgnc:11103

chromatin remodeling GO:0006338 ↓ DECREASED

Downstream

Merlin Loss and Schwann-Cell Tumorigenesis SWI/SNF dysfunction cooperates with NF2/merlin loss to drive tumorigenesis.

Meningioma SMARCB1-related tumor predisposition can include meningioma.

LZTR1-CUL3 Substrate Adaptor Dysfunction

LZTR1 functions as a substrate-specific adaptor for the CUL3 E3 ubiquitin ligase, targeting substrates including RAS GTPases for ubiquitination and membrane-level regulation. Loss of LZTR1 impairs this ubiquitin-mediated control and can enhance RAS-MAPK signaling, contributing to Schwann-cell proliferation in LZTR1-related schwannomatosis.

Schwann cell CL:0002573

LZTR1 hgnc:6742

protein ubiquitination GO:0016567 ↓ DECREASED Ras protein signal transduction GO:0007265 ↑ INCREASED

Downstream

Merlin Loss and Schwann-Cell Tumorigenesis Dysregulated RAS-MAPK cooperates with NF2/merlin loss to drive schwannoma formation.

Show evidence (1 reference)

PMID:24362817 SUPPORT Human Clinical

"Our findings identify LZTR1 as a gene predisposing to an autosomal dominant inherited disorder of multiple schwannomas in ∼80% of 22q-related schwannomatosis cases lacking mutation in SMARCB1."

Identifies germline LZTR1 loss-of-function as the predisposing event in the majority of SMARCB1-negative 22q-related schwannomatosis.

Merlin Loss and Schwann-Cell Tumorigenesis

Somatic biallelic NF2 inactivation eliminates the tumor suppressor merlin/schwannomin, the convergent effector shared with sporadic and NF2-related schwannoma. Merlin loss removes contact-dependent growth inhibition and de-represses mitogenic and Hippo/YAP-TAZ signaling, driving clonal proliferation of neoplastic Schwann cells into multiple benign schwannomas.

Schwann cell CL:0002573

NF2 hgnc:7773

Schwann cell proliferation GO:0014010 ↑ INCREASED

peripheral nervous system UBERON:0000010

Downstream

Multiple Non-Intradermal Schwannomas Merlin loss drives clonal Schwann-cell proliferation into multiple non-intradermal schwannomas.

Chronic Neuropathic Pain Schwannomas of peripheral and spinal nerves generate chronic, often debilitating pain.

Show evidence (2 references)

PMID:36944680 SUPPORT In Vitro

"Virtually all schwannomas result from inactivation of the NF2 tumor suppressor gene with few, if any, cooperating mutations."

Establishes NF2/merlin inactivation as the convergent driver of schwannoma, the shared effector in schwannomatosis tumors.

PMID:36944680 SUPPORT In Vitro

"loss of the membrane:cytoskeleton-associated NF2 tumor suppressor, merlin, yields unstable intrinsic polarity and enables Nf2-/- Schwann cells to adopt distinct programs of ErbB ligand production and polarized signaling"

Describes how merlin loss drives dysregulated Schwann-cell signaling underlying schwannoma growth.

Chronic Neuropathic Pain

Multiple schwannomas impinging on peripheral and spinal nerves produce chronic, often severe pain that is the most prominent and most frequently presenting clinical feature of schwannomatosis, distinguishing it clinically from NF2-related disease.

Schwann cell CL:0002573

peripheral nervous system UBERON:0000010

Downstream

Chronic Pain Schwannoma-related nerve irritation manifests clinically as chronic pain.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

3

Constitutional 1

Chronic Pain Chronic pain HP:0012532

Temporal: CHRONIC

Show evidence (1 reference)

PMID:29517885 SUPPORT Human Clinical

"The most common presenting feature is localized or diffuse pain or asymptomatic mass."

GeneReviews identifies pain as the most common presenting feature of schwannomatosis.

Neoplasm 1

Meningioma Meningioma HP:0002858

Show evidence (1 reference)

PMID:29517885 SUPPORT Human Clinical

"Meningiomas have only been reported in individuals with SMARCB1-related schwannomatosis."

GeneReviews supports meningioma as a SMARCB1-related-specific feature of schwannomatosis.

Other 1

Multiple Non-Intradermal Schwannomas Schwannoma HP:0100008

Show evidence (2 references)

PMID:29517885 SUPPORT Human Clinical

"LZTR1- and SMARCB1-related schwannomatosis are characterized by a predisposition to develop multiple non-intradermal schwannomas."

GeneReviews defines schwannomatosis by multiple non-intradermal schwannomas.

PMID:29517885 SUPPORT Human Clinical

"Schwannomas most often affect peripheral nerves and spinal nerves."

Supports the peripheral and spinal nerve distribution of schwannomas.

Context-specific annotations (1)

Onset: YOUNG_ADULT; 10-40y

GeneReviews reports that affected individuals most commonly present between the second and fourth decade of life.

Show evidence (1 reference)

PMID:29517885 SUPPORT Human Clinical

"Individuals most commonly present between the second and fourth decade of life."

Supports young-adult age of onset (second to fourth decade) for schwannomatosis.

🧬

Genetic Associations

2

SMARCB1 germline pathogenic variant (Germline loss-of-function variants in SMARCB1 cause SMARCB1-related schwannomatosis, with elevated malignancy and meningioma risk.)

Gene: SMARCB1 hgnc:11103 relationship_type: CAUSATIVE

Autosomal dominant

Show evidence (2 references)

PMID:29517885 SUPPORT Human Clinical

"The diagnosis of LZTR1- or SMARCB1-related schwannomatosis is established in a proband with characteristic clinical findings and a heterozygous germline pathogenic variant in LZTR1 or SMARCB1 identified by molecular genetic testing."

Supports germline SMARCB1 variants as causative.

PMID:39209702 SUPPORT Human Clinical

"We found that 17 (11%) people from 13 families had a germline SMARCB1 variant and 19 (12%) unrelated individuals had a germline LZTR1 variant."

Cohort data quantifying germline SMARCB1 and LZTR1 variant yields in clinically suspected schwannomatosis.

LZTR1 germline pathogenic variant (Germline loss-of-function variants in LZTR1 cause LZTR1-related schwannomatosis, including a risk of unilateral vestibular schwannoma.)

Gene: LZTR1 hgnc:6742 relationship_type: CAUSATIVE

Autosomal dominant

Show evidence (2 references)

PMID:29517885 SUPPORT Human Clinical

"The diagnosis of LZTR1- or SMARCB1-related schwannomatosis is established in a proband with characteristic clinical findings and a heterozygous germline pathogenic variant in LZTR1 or SMARCB1 identified by molecular genetic testing."

Supports germline LZTR1 variants as causative.

PMID:24362817 SUPPORT Human Clinical

"LZTR1 germline mutations were identified in seven of the eight cases."

Primary report identifying germline LZTR1 mutations in SMARCB1-negative schwannomatosis families.

💊

Medical Actions

4

Microsurgical Resection

Action: surgical procedure MAXO:0000004

Surgical removal is the mainstay for symptomatic or growing schwannomas, indicated for tumors causing uncontrolled localized pain or a neurologic deficit.

Show evidence (1 reference)

PMID:29517885 SUPPORT Human Clinical

"surgery for schwannomas associated with uncontrolled localized pain or a neurologic deficit"

GeneReviews supports surgical resection for symptomatic schwannomas.

Active Surveillance

Action: surveillance for malignancies MAXO:0001492

Periodic neurologic examination, pain assessment, and brain/spine or whole-body MRI surveillance are recommended for schwannomatosis patients.

Show evidence (1 reference)

PMID:29517885 SUPPORT Human Clinical

"Annual neurologic examination and pain assessment; brain and spine MRI or whole-body MRI every two to three years beginning at age 12 years"

GeneReviews supports surveillance imaging and neurologic monitoring.

Radiation Avoidance

Action: therapeutic procedure Ontology label: Therapeutic Procedure NCIT:C49236

Therapeutic radiation should be avoided when possible in schwannomatosis because it can increase the risk of malignant transformation of nerve sheath tumors. This is the principal "agents/circumstances to avoid" management recommendation in GeneReviews.

Show evidence (1 reference)

PMID:29517885 SUPPORT Human Clinical

"Radiation can increase the risk for malignant transformation and should be avoided when possible."

GeneReviews lists radiation avoidance as a key agents/circumstances-to-avoid recommendation because radiation increases malignant-transformation risk.

Multimodal Pain Management

Action: therapeutic procedure Ontology label: Therapeutic Procedure NCIT:C49236

Because chronic pain is the dominant and often treatment-resistant symptom of schwannomatosis, GeneReviews recommends a comprehensive, multimodal approach to pain management guided by a pain specialist or neurologist.

Target Phenotypes: Chronic pain HP:0012532

Show evidence (1 reference)

PMID:29517885 SUPPORT Human Clinical

"Comprehensive, multimodal approach to pain management, guided by a pain management specialist or neurologist"

GeneReviews supports multimodal pain management as central to schwannomatosis care.

🔬

Clinical Trials

2

NCT04163419 PHASE_II UNKNOWN

Randomized, double-blind, placebo-controlled study of the anti-NGF antibody tanezumab for moderate-to-severe pain due to schwannomatosis, targeting the syndrome's dominant chronic-pain phenotype.

Target Phenotypes: Chronic pain HP:0012532

Show evidence (1 reference)

clinicaltrials:NCT04163419 SUPPORT

"improves pain relief in schwannomatosis patients receiving background non-NSAID therapy"

A registered interventional trial targeting schwannomatosis-associated chronic pain, the syndrome's dominant symptom.

NCT05684692 PHASE_II RECRUITING

STARFISH — a placebo-controlled, multi-arm phase II platform screening trial testing multiple experimental therapies (including siltuximab, an anti-IL-6 antibody, and erenumab, a CGRP-receptor antibody) for moderate-to-severe pain due to schwannomatosis, the syndrome's dominant chronic-pain phenotype.

Target Phenotypes: Chronic pain HP:0012532

Show evidence (1 reference)

clinicaltrials:NCT05684692 SUPPORT

"phase II platform screening trial designed to test the safety, pain responses, and pharmacodynamic activity of multiple experimental therapies simultaneously in participants with moderate-to-severe pain due to schwannomatosis"

A registered phase II platform trial screening multiple agents for schwannomatosis-associated chronic pain, the syndrome's dominant symptom.

{ }

Source YAML

click to show

name: Schwannomatosis
creation_date: "2026-06-08T00:00:00Z"
category: Neoplastic
categories:
- Tumor Predisposition Syndrome
- Peripheral Nerve Sheath Tumor
synonyms:
- neurofibromatosis type 3
- NF3
- SMARCB1-related schwannomatosis
- LZTR1-related schwannomatosis
- non-NF2 schwannomatosis
disease_term:
  preferred_term: schwannomatosis
  term:
    id: MONDO:0008075
    label: schwannomatosis
description: >-
  Schwannomatosis is a hereditary tumor-predisposition syndrome characterized by
  the development of multiple non-intradermal schwannomas of peripheral, spinal,
  and cranial nerves, classically sparing the vestibular nerves (distinguishing
  it from NF2-related schwannomatosis). Chronic, often debilitating pain is the
  most prominent and frequently presenting clinical feature. The syndrome is
  caused by germline loss-of-function variants in SMARCB1 (a core subunit of the
  SWI/SNF chromatin-remodeling complex) or LZTR1 (a CUL3 ubiquitin-ligase
  substrate adaptor), with a characteristic composite "4-hit/3-event" molecular
  mechanism: a germline first hit in SMARCB1 or LZTR1, somatic loss of the
  remaining wild-type SMARCB1/LZTR1 allele, and somatic biallelic inactivation of
  the NF2 tumor-suppressor gene — all three genes residing on chromosome 22q,
  such that a single 22q event can co-delete the predisposition gene and one NF2
  allele. SMARCB1-related disease is associated with a higher risk of malignancy
  and meningioma, whereas LZTR1-related disease can include unilateral vestibular
  schwannoma. A substantial fraction of clinically diagnosed schwannomatosis has
  no identified germline SMARCB1 or LZTR1 variant (22q-related/unknown-gene
  schwannomatosis).
parents:
- nerve sheath tumor predisposition syndrome
- hereditary neoplastic syndrome
references:
- reference: PMID:29517885
  title: "LZTR1- and SMARCB1-Related Schwannomatosis."
  tags:
  - GeneReviews
has_subtypes:
- name: SMARCB1-related
  display_name: SMARCB1-related Schwannomatosis
  classification: genetic
  subtype_term:
    preferred_term: SMARCB1-related schwannomatosis
    term:
      id: MONDO:0024517
      label: SMARCB1-related schwannomatosis
  description: >-
    Schwannomatosis caused by a germline pathogenic variant in SMARCB1 (INI1/BAF47),
    a core subunit of the SWI/SNF chromatin-remodeling complex on chromosome 22q11.
    Accounts for roughly half of familial schwannomatosis. Carries an elevated risk
    of malignant peripheral nerve sheath tumor and of meningioma relative to
    LZTR1-related disease.
  inheritance:
  - name: Autosomal dominant
  genes:
  - preferred_term: SMARCB1
    term:
      id: hgnc:11103
      label: SMARCB1
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Malignancy remains a risk especially in individuals with SMARCB1-related schwannomatosis."
    explanation: GeneReviews notes the elevated malignancy risk in SMARCB1-related schwannomatosis.
  - reference: PMID:24362817
    reference_title: "Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Constitutional SMARCB1 mutations at 22q11.23 have been found in ∼50% of familial and <10% of sporadic schwannomatosis cases."
    explanation: Quantifies the contribution of germline SMARCB1 mutations to familial and sporadic schwannomatosis.
- name: LZTR1-related
  display_name: LZTR1-related Schwannomatosis
  classification: genetic
  subtype_term:
    preferred_term: LZTR1-related schwannomatosis
    term:
      id: MONDO:0014299
      label: LZTR1-related schwannomatosis
  description: >-
    Schwannomatosis caused by a germline pathogenic variant in LZTR1, a CUL3
    ubiquitin-ligase substrate adaptor on chromosome 22q11. Associated with
    multiple non-intradermal schwannomas and, unlike SMARCB1-related disease, a
    recognized risk of unilateral vestibular schwannoma.
  inheritance:
  - name: Autosomal dominant
  genes:
  - preferred_term: LZTR1
    term:
      id: hgnc:6742
      label: LZTR1
  evidence:
  - reference: PMID:24362817
    reference_title: "Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our findings identify LZTR1 as a gene predisposing to an autosomal dominant inherited disorder of multiple schwannomas in ∼80% of 22q-related schwannomatosis cases lacking mutation in SMARCB1."
    explanation: Piotrowski 2014 is the primary LZTR1 discovery paper, identifying germline LZTR1 loss of function as the predisposing event in most SMARCB1-negative 22q-related schwannomatosis.
- name: 22q-related/unknown-gene
  display_name: 22q-related / Unknown-gene Schwannomatosis
  classification: genetic
  description: >-
    Clinically diagnosed schwannomatosis in which no germline SMARCB1 or LZTR1
    pathogenic variant is identified. A substantial proportion of patients —
    particularly sporadic cases — fall into this category, reflecting either
    undetected variants in known genes, mosaic NF2 disease detectable mainly by
    tumor testing, or as-yet-unidentified predisposition genes.
  evidence:
  - reference: PMID:39209702
    reference_title: "Genetic findings in people with schwannomas who do not meet clinical diagnostic criteria for NF2-related schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "19 people had an NF2 variant, but 18 of these were mosaic and 17 were only detected when 2 tumours were available for testing."
    explanation: Documents that many schwannomatosis cases without a germline SMARCB1/LZTR1 variant are explained by mosaic NF2 detectable only on tumor testing.
  - reference: PMID:39209702
    reference_title: "Genetic findings in people with schwannomas who do not meet clinical diagnostic criteria for NF2-related schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The overall detection rate was 25% using blood alone, but increased to 36% when tumour analysis was included."
    explanation: Supports that a large fraction of clinically diagnosed schwannomatosis lacks an identifiable germline variant on blood testing.
pathophysiology:
- name: Germline SMARCB1 or LZTR1 Loss of Function (First Hit)
  description: >-
    The predisposing event is a germline loss-of-function variant in SMARCB1
    (a core SWI/SNF chromatin-remodeling subunit) or LZTR1 (a CUL3 ubiquitin-ligase
    substrate adaptor), both located on chromosome 22q. This heterozygous germline
    "first hit" sensitizes Schwann-cell precursors to subsequent somatic events
    that complete tumorigenesis.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  genes:
  - preferred_term: SMARCB1
    term:
      id: hgnc:11103
      label: SMARCB1
  - preferred_term: LZTR1
    term:
      id: hgnc:6742
      label: LZTR1
  downstream:
  - target: Composite 4-Hit/3-Event 22q Inactivation
    description: The germline first hit is followed by somatic loss of the other allele and biallelic NF2 inactivation.
  - target: SMARCB1 SWI/SNF Chromatin-Remodeling Dysfunction
    description: Germline SMARCB1 loss of function impairs SWI/SNF (BAF) chromatin-remodeling activity in Schwann-cell precursors.
  - target: LZTR1-CUL3 Substrate Adaptor Dysfunction
    description: Germline LZTR1 loss of function impairs CUL3-mediated substrate ubiquitination, dysregulating RAS-MAPK signaling.
- name: Composite 4-Hit/3-Event 22q Inactivation
  description: >-
    Schwannomas in SMARCB1/LZTR1-related schwannomatosis arise through a
    characteristic composite mechanism involving four mutational hits across three
    events: the germline first hit in SMARCB1 or LZTR1, somatic inactivation of the
    remaining wild-type SMARCB1/LZTR1 allele, and somatic biallelic inactivation of
    NF2. Because SMARCB1, LZTR1, and NF2 all lie on chromosome 22q, a single somatic
    loss of one 22q copy can simultaneously remove the remaining predisposition-gene
    allele and one NF2 allele, leaving a second somatic NF2 mutation to complete the
    process.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  genes:
  - preferred_term: NF2
    term:
      id: hgnc:7773
      label: NF2
  biological_processes:
  - preferred_term: negative regulation of cell population proliferation
    modifier: DECREASED
    term:
      id: GO:0008285
      label: negative regulation of cell population proliferation
  evidence:
  - reference: PMID:18072270
    reference_title: "Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A novel germline SMARCB1 mutation was found in one patient; inactivating somatic mutations of NF2, associated with loss of heterozygosity (LOH) of 22q, were found in two schwannomas of this patient."
    explanation: Documents the germline SMARCB1 first hit plus somatic NF2 inactivation with 22q LOH in schwannomatosis tumors.
  - reference: PMID:18072270
    reference_title: "Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a four-hit mechanism involving the SMARCB1 and NF2 genes may be implicated in schwannomatosis-related tumorigenesis"
    explanation: Establishes the composite four-hit SMARCB1/NF2 mechanism underlying schwannomatosis tumorigenesis.
  - reference: PMID:24362817
    reference_title: "Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "schwannomas involved somatic loss of one copy of 22q, encompassing SMARCB1 and NF2, with a different somatic mutation of the other NF2 allele in every schwannoma"
    explanation: Documents the 22q loss co-removing the predisposition gene and one NF2 allele plus a second somatic NF2 mutation, the core of the 4-hit/3-event mechanism.
  downstream:
  - target: Merlin Loss and Schwann-Cell Tumorigenesis
    description: Biallelic NF2 inactivation eliminates merlin, the shared effector driving schwannoma growth.
- name: SMARCB1 SWI/SNF Chromatin-Remodeling Dysfunction
  description: >-
    SMARCB1 (INI1/BAF47) is a core subunit of the SWI/SNF (BAF) ATP-dependent
    chromatin-remodeling complex. Loss of SMARCB1 impairs SWI/SNF-mediated
    nucleosome remodeling and gene regulation, contributing to Schwann-cell
    transformation and underlying the higher malignancy risk in SMARCB1-related
    disease (epithelioid morphology with INI1 loss).
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  genes:
  - preferred_term: SMARCB1
    term:
      id: hgnc:11103
      label: SMARCB1
  biological_processes:
  - preferred_term: chromatin remodeling
    modifier: DECREASED
    term:
      id: GO:0006338
      label: chromatin remodeling
  downstream:
  - target: Merlin Loss and Schwann-Cell Tumorigenesis
    description: SWI/SNF dysfunction cooperates with NF2/merlin loss to drive tumorigenesis.
  - target: Meningioma
    description: SMARCB1-related tumor predisposition can include meningioma.
- name: LZTR1-CUL3 Substrate Adaptor Dysfunction
  description: >-
    LZTR1 functions as a substrate-specific adaptor for the CUL3 E3 ubiquitin
    ligase, targeting substrates including RAS GTPases for ubiquitination and
    membrane-level regulation. Loss of LZTR1 impairs this ubiquitin-mediated
    control and can enhance RAS-MAPK signaling, contributing to Schwann-cell
    proliferation in LZTR1-related schwannomatosis.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  genes:
  - preferred_term: LZTR1
    term:
      id: hgnc:6742
      label: LZTR1
  biological_processes:
  - preferred_term: protein ubiquitination
    modifier: DECREASED
    term:
      id: GO:0016567
      label: protein ubiquitination
  - preferred_term: Ras protein signal transduction
    modifier: INCREASED
    term:
      id: GO:0007265
      label: Ras protein signal transduction
  evidence:
  - reference: PMID:24362817
    reference_title: "Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our findings identify LZTR1 as a gene predisposing to an autosomal dominant inherited disorder of multiple schwannomas in ∼80% of 22q-related schwannomatosis cases lacking mutation in SMARCB1."
    explanation: Identifies germline LZTR1 loss-of-function as the predisposing event in the majority of SMARCB1-negative 22q-related schwannomatosis.
  downstream:
  - target: Merlin Loss and Schwann-Cell Tumorigenesis
    description: Dysregulated RAS-MAPK cooperates with NF2/merlin loss to drive schwannoma formation.
- name: Merlin Loss and Schwann-Cell Tumorigenesis
  description: >-
    Somatic biallelic NF2 inactivation eliminates the tumor suppressor
    merlin/schwannomin, the convergent effector shared with sporadic and NF2-related
    schwannoma. Merlin loss removes contact-dependent growth inhibition and
    de-represses mitogenic and Hippo/YAP-TAZ signaling, driving clonal proliferation
    of neoplastic Schwann cells into multiple benign schwannomas.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  genes:
  - preferred_term: NF2
    term:
      id: hgnc:7773
      label: NF2
  locations:
  - preferred_term: peripheral nervous system
    term:
      id: UBERON:0000010
      label: peripheral nervous system
  biological_processes:
  - preferred_term: Schwann cell proliferation
    modifier: INCREASED
    term:
      id: GO:0014010
      label: Schwann cell proliferation
  evidence:
  - reference: PMID:36944680
    reference_title: "Cellular mechanisms of heterogeneity in NF2-mutant schwannoma."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Virtually all schwannomas result from inactivation of the NF2 tumor suppressor gene with few, if any, cooperating mutations."
    explanation: Establishes NF2/merlin inactivation as the convergent driver of schwannoma, the shared effector in schwannomatosis tumors.
  - reference: PMID:36944680
    reference_title: "Cellular mechanisms of heterogeneity in NF2-mutant schwannoma."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "loss of the membrane:cytoskeleton-associated NF2 tumor suppressor, merlin, yields unstable intrinsic polarity and enables Nf2-/- Schwann cells to adopt distinct programs of ErbB ligand production and polarized signaling"
    explanation: Describes how merlin loss drives dysregulated Schwann-cell signaling underlying schwannoma growth.
  downstream:
  - target: Multiple Non-Intradermal Schwannomas
    description: Merlin loss drives clonal Schwann-cell proliferation into multiple non-intradermal schwannomas.
  - target: Chronic Neuropathic Pain
    description: Schwannomas of peripheral and spinal nerves generate chronic, often debilitating pain.
- name: Chronic Neuropathic Pain
  description: >-
    Multiple schwannomas impinging on peripheral and spinal nerves produce
    chronic, often severe pain that is the most prominent and most frequently
    presenting clinical feature of schwannomatosis, distinguishing it clinically
    from NF2-related disease.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  locations:
  - preferred_term: peripheral nervous system
    term:
      id: UBERON:0000010
      label: peripheral nervous system
  downstream:
  - target: Chronic Pain
    description: Schwannoma-related nerve irritation manifests clinically as chronic pain.
phenotypes:
- name: Multiple Non-Intradermal Schwannomas
  description: >-
    The defining manifestation is multiple benign Schwann-cell tumors of
    peripheral, spinal, and cranial nerves, characteristically sparing the
    vestibular nerves.
  phenotype_term:
    preferred_term: Schwannoma
    term:
      id: HP:0100008
      label: Schwannoma
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LZTR1- and SMARCB1-related schwannomatosis are characterized by a predisposition to develop multiple non-intradermal schwannomas."
    explanation: GeneReviews defines schwannomatosis by multiple non-intradermal schwannomas.
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Schwannomas most often affect peripheral nerves and spinal nerves."
    explanation: Supports the peripheral and spinal nerve distribution of schwannomas.
  phenotype_contexts:
  - onset:
      onset_category: YOUNG_ADULT
      min_age_years: 10
      max_age_years: 40
    notes: GeneReviews reports that affected individuals most commonly present between the second and fourth decade of life.
    evidence:
    - reference: PMID:29517885
      reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Individuals most commonly present between the second and fourth decade of life."
      explanation: Supports young-adult age of onset (second to fourth decade) for schwannomatosis.
- name: Chronic Pain
  description: >-
    Chronic, often debilitating pain is the most prominent and most frequently
    presenting feature of schwannomatosis.
  phenotype_term:
    preferred_term: Chronic pain
    term:
      id: HP:0012532
      label: Chronic pain
    temporality: CHRONIC
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common presenting feature is localized or diffuse pain or asymptomatic mass."
    explanation: GeneReviews identifies pain as the most common presenting feature of schwannomatosis.
- name: Meningioma
  subtype: SMARCB1-related
  description: >-
    Meningioma occurs in schwannomatosis and has been reported only in
    SMARCB1-related disease.
  phenotype_term:
    preferred_term: Meningioma
    term:
      id: HP:0002858
      label: Meningioma
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Meningiomas have only been reported in individuals with SMARCB1-related schwannomatosis."
    explanation: GeneReviews supports meningioma as a SMARCB1-related-specific feature of schwannomatosis.
genetic:
- name: SMARCB1 germline pathogenic variant
  gene_term:
    preferred_term: SMARCB1
    term:
      id: hgnc:11103
      label: SMARCB1
  association: >-
    Germline loss-of-function variants in SMARCB1 cause SMARCB1-related
    schwannomatosis, with elevated malignancy and meningioma risk.
  relationship_type: CAUSATIVE
  inheritance:
  - name: Autosomal dominant
    penetrance: INCOMPLETE
    evidence:
    - reference: PMID:29517885
      reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "inherited in an autosomal dominant manner with reduced penetrance"
      explanation: GeneReviews establishes autosomal dominant inheritance with reduced penetrance.
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of LZTR1- or SMARCB1-related schwannomatosis is established in a proband with characteristic clinical findings and a heterozygous germline pathogenic variant in LZTR1 or SMARCB1 identified by molecular genetic testing."
    explanation: Supports germline SMARCB1 variants as causative.
  - reference: PMID:39209702
    reference_title: "Genetic findings in people with schwannomas who do not meet clinical diagnostic criteria for NF2-related schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found that 17 (11%) people from 13 families had a germline SMARCB1 variant and 19 (12%) unrelated individuals had a germline LZTR1 variant."
    explanation: Cohort data quantifying germline SMARCB1 and LZTR1 variant yields in clinically suspected schwannomatosis.
- name: LZTR1 germline pathogenic variant
  gene_term:
    preferred_term: LZTR1
    term:
      id: hgnc:6742
      label: LZTR1
  association: >-
    Germline loss-of-function variants in LZTR1 cause LZTR1-related
    schwannomatosis, including a risk of unilateral vestibular schwannoma.
  relationship_type: CAUSATIVE
  inheritance:
  - name: Autosomal dominant
    penetrance: INCOMPLETE
    evidence:
    - reference: PMID:29517885
      reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "inherited in an autosomal dominant manner with reduced penetrance"
      explanation: GeneReviews establishes autosomal dominant inheritance with reduced penetrance.
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of LZTR1- or SMARCB1-related schwannomatosis is established in a proband with characteristic clinical findings and a heterozygous germline pathogenic variant in LZTR1 or SMARCB1 identified by molecular genetic testing."
    explanation: Supports germline LZTR1 variants as causative.
  - reference: PMID:24362817
    reference_title: "Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LZTR1 germline mutations were identified in seven of the eight cases."
    explanation: Primary report identifying germline LZTR1 mutations in SMARCB1-negative schwannomatosis families.
treatments:
- name: Microsurgical Resection
  description: >-
    Surgical removal is the mainstay for symptomatic or growing schwannomas,
    indicated for tumors causing uncontrolled localized pain or a neurologic
    deficit.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "surgery for schwannomas associated with uncontrolled localized pain or a neurologic deficit"
    explanation: GeneReviews supports surgical resection for symptomatic schwannomas.
- name: Active Surveillance
  description: >-
    Periodic neurologic examination, pain assessment, and brain/spine or whole-body
    MRI surveillance are recommended for schwannomatosis patients.
  treatment_term:
    preferred_term: surveillance for malignancies
    term:
      id: MAXO:0001492
      label: surveillance for malignancies
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Annual neurologic examination and pain assessment; brain and spine MRI or whole-body MRI every two to three years beginning at age 12 years"
    explanation: GeneReviews supports surveillance imaging and neurologic monitoring.
- name: Radiation Avoidance
  description: >-
    Therapeutic radiation should be avoided when possible in schwannomatosis
    because it can increase the risk of malignant transformation of nerve sheath
    tumors. This is the principal "agents/circumstances to avoid" management
    recommendation in GeneReviews.
  treatment_term:
    preferred_term: therapeutic procedure
    term:
      id: NCIT:C49236
      label: Therapeutic Procedure
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Radiation can increase the risk for malignant transformation and should be avoided when possible."
    explanation: GeneReviews lists radiation avoidance as a key agents/circumstances-to-avoid recommendation because radiation increases malignant-transformation risk.
- name: Multimodal Pain Management
  description: >-
    Because chronic pain is the dominant and often treatment-resistant symptom of
    schwannomatosis, GeneReviews recommends a comprehensive, multimodal approach to
    pain management guided by a pain specialist or neurologist.
  treatment_term:
    preferred_term: therapeutic procedure
    term:
      id: NCIT:C49236
      label: Therapeutic Procedure
  target_phenotypes:
  - preferred_term: Chronic pain
    term:
      id: HP:0012532
      label: Chronic pain
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Comprehensive, multimodal approach to pain management, guided by a pain management specialist or neurologist"
    explanation: GeneReviews supports multimodal pain management as central to schwannomatosis care.
clinical_trials:
- name: NCT04163419
  phase: PHASE_II
  status: UNKNOWN
  description: >-
    Randomized, double-blind, placebo-controlled study of the anti-NGF antibody
    tanezumab for moderate-to-severe pain due to schwannomatosis, targeting the
    syndrome's dominant chronic-pain phenotype.
  target_phenotypes:
  - preferred_term: Chronic pain
    term:
      id: HP:0012532
      label: Chronic pain
  evidence:
  - reference: clinicaltrials:NCT04163419
    supports: SUPPORT
    snippet: "improves pain relief in schwannomatosis patients receiving background non-NSAID therapy"
    explanation: A registered interventional trial targeting schwannomatosis-associated chronic pain, the syndrome's dominant symptom.
- name: NCT05684692
  phase: PHASE_II
  status: RECRUITING
  description: >-
    STARFISH — a placebo-controlled, multi-arm phase II platform screening trial
    testing multiple experimental therapies (including siltuximab, an anti-IL-6
    antibody, and erenumab, a CGRP-receptor antibody) for moderate-to-severe pain
    due to schwannomatosis, the syndrome's dominant chronic-pain phenotype.
  target_phenotypes:
  - preferred_term: Chronic pain
    term:
      id: HP:0012532
      label: Chronic pain
  evidence:
  - reference: clinicaltrials:NCT05684692
    supports: SUPPORT
    snippet: "phase II platform screening trial designed to test the safety, pain responses, and pharmacodynamic activity of multiple experimental therapies simultaneously in participants with moderate-to-severe pain due to schwannomatosis"
    explanation: A registered phase II platform trial screening multiple agents for schwannomatosis-associated chronic pain, the syndrome's dominant symptom.

📚

References & Deep Research

References

1

PMID:29517885

LZTR1- and SMARCB1-Related Schwannomatosis.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 42 citations 2026-06-08T18:17:33.667145

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Schwannomatosis
MONDO ID: (if available)
Category: Neoplastic

Research Objectives

Please provide a comprehensive research report on Schwannomatosis covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Schwannomatosis — Comprehensive Disease Characteristics Report (Neoplastic)

Target Disease

Disease name: Schwannomatosis
Category: Neoplastic (benign peripheral nerve sheath tumor predisposition syndrome)
MONDO ID: MONDO:0008075 (schwannomatosis) (OpenTargets Search: Schwannomatosis)

Executive summary (current understanding)

Schwannomatosis is now used as an umbrella term (internationally updated in 2022) for inherited tumor-predisposition syndromes characterized by development of multiple schwannomas, and subdivided by the causal gene (e.g., NF2-related schwannomatosis, SMARCB1-related schwannomatosis, LZTR1-related schwannomatosis) rather than older “NF2 vs schwannomatosis” separation. (tamura2024historicaldevelopmentof pages 1-3, nagasaka2025geneticbasisand pages 1-2, rai2025classificationofschwannomas pages 1-2)

Two key clinical axes dominate disease burden and real-world management: 1) Tumor burden (schwannomas; plus meningiomas/ependymomas in NF2-related forms). (tamura2024historicaldevelopmentof pages 1-3, evans2025historyandclinical pages 1-2) 2) Pain and quality-of-life impairment, often not well correlated with tumor size/burden. (nagasaka2025geneticbasisand pages 1-2, chiassonmackenzie2023cellularmechanismsof pages 1-2)

1. Disease information

1.1 What is the disease?

Schwannomatosis comprises gene-defined tumor predisposition syndromes marked by multiple schwannomas (benign peripheral nerve sheath tumors), often affecting cranial, spinal, and peripheral nerves; NF2-related schwannomatosis also features meningiomas and sometimes ependymomas. (tamura2024historicaldevelopmentof pages 1-3, perrino2025updateoncancer pages 5-7, evans2025historyandclinical pages 1-2)

Direct abstract quote (definition/nomenclature): - Tamura et al. (2024) state that the 2022 expert committee “recommended the use of ‘schwannomatosis’ as an umbrella term for conditions that predispose to schwannomas” and that “Each type of schwannomatosis was classified by the gene containing the disease-causing pathogenic variant.” (Published online 2024-06-19; Neurologia medico-chirurgica) (tamura2024historicaldevelopmentof pages 1-3)

1.2 Key identifiers

Available from current tool-derived evidence (MONDO/OpenTargets): - MONDO:0008075 schwannomatosis. (OpenTargets Search: Schwannomatosis) - Related MONDO subtype entities observed: NF2-related schwannomatosis (MONDO:0007039), SMARCB1-related schwannomatosis (MONDO:0024517), LZTR1-related schwannomatosis (MONDO:0014299). (OpenTargets Search: Schwannomatosis)

Not retrieved in the present evidence set: OMIM, Orphanet (ORPHA), ICD-10/ICD-11, and MeSH identifiers were not directly retrievable from the documents/tools accessed in this run; these should be added by querying OMIM/Orphanet/MeSH directly in a complementary curation step. (evidence gap)

1.3 Synonyms / alternative names

NF2-related schwannomatosis: formerly “neurofibromatosis type 2 (NF2)”. (tamura2024historicaldevelopmentof pages 1-3, rai2025classificationofschwannomas pages 1-2)
“Schwannomatosis” historically overlapped with terms such as “neurilemmomatosis” and earlier NF2 diagnostic framing, but modern usage is gene-based. (tamura2024historicaldevelopmentof pages 1-3)

1.4 Evidence source type

This report is primarily derived from: - Aggregated disease-level resources and consensus reviews (e.g., 2024 diagnostic criteria evolution review). (tamura2024historicaldevelopmentof pages 1-3) - Human cohorts undergoing genetic testing. (smith2024geneticfindingsin pages 1-5) - ClinicalTrials.gov trial registry records (real-world implementations of experimental therapeutics). (NCT05684692 chunk 1, NCT04163419 chunk 1, NCT04374305 chunk 1) - Mechanistic preclinical research (mouse + cell systems) for NF2-mutant schwannoma biology. (chiassonmackenzie2023cellularmechanismsof pages 1-2)

2. Etiology

2.1 Disease causal factors

Primary cause: inherited (or mosaic) pathogenic variants predisposing to schwannoma formation, most commonly involving chromosome 22 genes: - NF2 (merlin tumor suppressor) → NF2-related schwannomatosis; mosaicism is common in de novo disease. (tamura2024historicaldevelopmentof pages 1-3, evans2025historyandclinical pages 1-2) - SMARCB1 and LZTR1 → non-NF2 schwannomatosis forms, with characteristic multi-hit tumorigenesis involving chromosome 22 loss and somatic NF2 events. (tamura2024historicaldevelopmentof pages 3-4, nagasaka2025geneticbasisand pages 1-2)

Quantitative contribution (familial vs isolated, from a recent diagnostic criteria review): - SMARCB1/LZTR1 “account for 70%–85% of familial schwannomatosis and 30%–40% of isolated cases.” (Tamura et al., 2024) (tamura2024historicaldevelopmentof pages 3-4)

2.2 Risk factors

Genetic risk factors

Pathogenic/likely pathogenic germline variants in NF2, SMARCB1, LZTR1 are the major recognized inherited risk factors. (OpenTargets Search: Schwannomatosis, perrino2025updateoncancer pages 5-7)
Mosaic NF2 is a frequent explanation for individuals with multiple schwannomas who do not meet classic clinical criteria; tumor-pair testing can reveal shared NF2 variants. (smith2024geneticfindingsin pages 1-5, tamura2024historicaldevelopmentof pages 3-4)

Cohort statistics (2024 J Med Genet): In 154 people with at least one non-vestibular schwannoma (not meeting NF2-SWN clinical criteria at time of testing): - Germline SMARCB1 variants: 17/154 (11%). - Germline LZTR1 variants: 19/154 (12%). - NF2 variants in 19 people, 18 mosaic, and 17 detected only when two tumors were available. - Diagnostic yield: 25% blood-only vs 36% with tumor analysis. (Smith et al., 2024; published 2024-08; Journal of Medical Genetics) (smith2024geneticfindingsin pages 1-5)

Environmental risk factors

No specific environmental exposures were identified in the retrieved evidence as established risk factors for schwannomatosis onset. (evidence gap)

2.3 Protective factors

No genetic or environmental protective factors were identified in the retrieved evidence set. (evidence gap)

2.4 Gene–environment interactions

No gene–environment interaction evidence was identified in the retrieved evidence set. (evidence gap)

3. Phenotypes

3.1 Core phenotype domains and suggested HPO terms

Below are common phenotype groupings supported by the retrieved evidence, with suggested HPO annotations (HPO terms provided as curation suggestions; exact IDs should be confirmed during ontology mapping):

1) Schwannomas (multiple) - HPO suggestion: Peripheral nerve schwannoma; Cranial nerve schwannoma; Spinal schwannoma. - Evidence: hallmark across schwannomatosis subtypes; NF2-related often with bilateral vestibular schwannomas. (perrino2025updateoncancer pages 5-7, evans2025historyandclinical pages 1-2)

2) Vestibular schwannoma / hearing and balance deficits (esp. NF2-related) - HPO suggestions: Hearing loss; Vestibular dysfunction; Tinnitus. - Evidence: NF2-related schwannomatosis commonly presents with bilateral vestibular schwannomas; Freier cohort reports hearing problems affecting activities. (evans2025historyandclinical pages 1-2, freier2024theimpactof pages 3-4)

3) Pain (chronic, often severe; especially non-NF2 forms) - HPO suggestions: Chronic pain; Neuropathic pain; Allodynia (if present); Painful peripheral nerve tumor. - Evidence: pain is a dominant symptom and may be poorly correlated with tumor burden. (nagasaka2025geneticbasisand pages 1-2, chiassonmackenzie2023cellularmechanismsof pages 1-2)

4) Meningioma and ependymoma (more typical in NF2-related) - HPO suggestions: Meningioma; Ependymoma. - Evidence: NF2-related syndromic spectrum includes meningiomas and less commonly ependymoma. (perrino2025updateoncancer pages 5-7, evans2025historyandclinical pages 1-2)

5) Psychological burden / QoL impairment (NF2-related evidence strongest in retrieved set) - HPO suggestions: Depressive mood; Anxiety; Reduced quality of life. - Evidence: depression/anxiety prevalence and QoL correlations in NF2-SWN. (freier2024theimpactof pages 1-2)

3.2 Age of onset and progression

NF2-related schwannomatosis is described as autosomal dominant with complete penetrance and progressive morbidities, with monitoring based on neurologic deficits, imaging, and audiometry. (freier2024theimpactof pages 1-2)
Schwannomas can have variable natural histories and growth rates, even within the same patient; pain/tumor burden correlation is weak. (chiassonmackenzie2023cellularmechanismsof pages 1-2)

3.3 Frequency / statistics for selected phenotypes

Pain frequency

In the tanezumab schwannomatosis pain trial registry record: “Pain is the most frequent symptom reported by these patients, with 68% experiencing chronic pain.” (ClinicalTrials.gov NCT04163419; last update posted 2024-03-13) (NCT04163419 chunk 1)

NF2-related QoL and mental health statistics (2024 peer-reviewed)

Freier et al. (Scientific Reports; published 2024-03) reported among NF2-SWN patients: - “Questionnaires were completed by 77 patients” and “Physician-rated disease severity scores were available for 55 patients.” (freier2024theimpactof pages 1-2) - “High prevalence of clinically relevant symptoms of depression (30%), anxiety (16%), and somatic burden (32%).” (freier2024theimpactof pages 1-2) - NF2-SWN-related QoL associated with physician severity r = 0.614, and a regression model explained 64% of variance in QoL. (freier2024theimpactof pages 1-2)

3.4 Quality of life impact

NF2-SWN: substantial psychosocial and functional burden; authors highlight strong association of QoL with depression symptoms and modifiable constructs (personality functioning). (freier2024theimpactof pages 1-2)
Schwannomatosis pain burden: pain is commonly chronic and treatment-resistant, and surgery can lead to persistent/recurrent pain due to nerve injury or recurrence. (hino2025optimaldeliveryof pages 1-2)

4. Genetic / molecular information

4.1 Causal genes (major)

NF2 (merlin tumor suppressor). (tamura2024historicaldevelopmentof pages 1-3)
SMARCB1 (SWI/SNF chromatin remodeling complex component). (madison2026schwannomatosistumormodeling pages 1-2)
LZTR1 (CUL3 adaptor; RAS ubiquitination regulator). (madison2026schwannomatosistumormodeling pages 1-2)

OpenTargets disease–target associations for schwannomatosis highlight LZTR1, SMARCB1, NF2. (OpenTargets Search: Schwannomatosis)

4.2 Pathogenic variants and variant spectrum (from retrieved evidence)

Mosaic NF2 is common and often requires tumor testing to identify; in the Manchester cohort, 18/19 NF2 findings were mosaic and most required testing of two tumors. (smith2024geneticfindingsin pages 1-5)
Detection quality requirements for somatic variants: neoplastic content ≥20% and deep sequencing (~1000× mean depth) were described for optimum detection. (smith2024geneticfindingsin pages 1-5)

Variant type examples (2026 case series; illustrates spectrum rather than frequency): NF2 alterations can include truncating variants, copy-number changes (whole-gene deletion), and in-frame indels with merlin loss, supporting need for comprehensive testing modalities (e.g., MLPA/WGS). (freier2024theimpactof pages 2-3)

4.3 Inheritance and penetrance

NF2-SWN described as autosomal dominant; Freier et al. describe “complete penetrance” in background. (freier2024theimpactof pages 1-2)
LZTR1-related schwannomatosis described as incompletely penetrant in surveillance perspective context. (perrino2025updateoncancer pages 5-7)

4.4 Multi-hit / tumorigenesis models

SMARCB1/LZTR1-related SWN: three-step/four-hit model involving retention of germline mutant allele, loss of the wild-type chromosome 22, and somatic NF2 mutation. (nagasaka2025geneticbasisand pages 1-2, tamura2024historicaldevelopmentof pages 3-4)

4.5 Epigenetic information

No schwannomatosis-specific epigenetic quantitative data were extracted from the 2023–2024 sources retrieved here; however, vestibular schwannoma reviews (not schwannomatosis-specific cohorts) discuss promoter methylation/transcriptional repression as potential functional “second hits” for NF2 and broader epigenetic regulation. (otaner2026vestibularschwannomagenetic pages 2-4)

5. Environmental information

No validated environmental, lifestyle, or infectious causal contributors were identified in the retrieved evidence set for schwannomatosis. (evidence gap)

6. Mechanism / pathophysiology

6.1 Causal chain (genotype → cell biology → tumors and symptoms)

A synthesis supported by mechanistic and clinical sources: 1) Upstream genetic loss: NF2/merlin loss (constitutional or somatic; often biallelic in tumor) (tamura2024historicaldevelopmentof pages 1-3, chiassonmackenzie2023cellularmechanismsof pages 1-2) 2) Schwann-cell polarity/signaling dysregulation: merlin loss yields unstable intrinsic polarity and distinct ErbB-ligand programs (chiassonmackenzie2023cellularmechanismsof pages 1-2) 3) Downstream pathway activation and heterogeneity: polarized ErbB signaling, mTOR outputs, and tumor heterogeneity; impacts therapeutic response variability (chiassonmackenzie2023cellularmechanismsof pages 1-2) 4) Clinical manifestations: schwannomas on cranial/spinal/peripheral nerves cause neurologic deficits and chronic pain; pain may not correlate with burden, suggesting additional biological drivers (e.g., local signaling, nerve–tumor interface) (chiassonmackenzie2023cellularmechanismsof pages 1-2)

6.2 Key pathways (examples) and GO term suggestions

NF2/merlin loss → heterogeneity mechanism (2023 Nature Communications) Direct abstract quote: - “Virtually all schwannomas result from inactivation of the NF2 tumor suppressor gene with few, if any, cooperating mutations” and “loss of…merlin…enables Nf2−/− Schwann cells to adopt distinct programs of ErbB ligand production and polarized signaling.” (Chiasson‑MacKenzie et al., 2023-03; Nature Communications) (chiassonmackenzie2023cellularmechanismsof pages 1-2)

GO Biological Process suggestions (curation): - Schwann cell differentiation / proliferation - Regulation of epithelial cell polarity / establishment of cell polarity - ERBB signaling pathway - mTOR signaling

6.3 Cell types and CL term suggestions

Primary tumor cell: Schwann cell (CL: Schwann cell).
Tumor microenvironment components: nerve cells, immune cells, stromal cells (general statement from modeling review). (madison2026schwannomatosistumormodeling pages 1-2)

6.4 Mechanistic models and experimental systems (model organism evidence)

Mouse and Schwann-cell systems were used to model NF2-mutant schwannoma heterogeneity; authors “exploited the synchronous development of lesions in a mouse model” to quantify heterogeneity evolution. (chiassonmackenzie2023cellularmechanismsof pages 1-2)

7. Anatomical structures affected

7.1 Organ/system level

Predominantly nervous system: cranial nerves (incl. vestibular nerve), spinal nerve roots, peripheral nerves. (smith2024geneticfindingsin pages 1-5, chiassonmackenzie2023cellularmechanismsof pages 1-2)
CNS tumors in NF2-SWN: meningiomas and sometimes ependymomas. (perrino2025updateoncancer pages 5-7, evans2025historyandclinical pages 1-2)

UBERON suggestions (curation): - Peripheral nerve; spinal nerve root; vestibulocochlear nerve; meninges; spinal cord.

7.2 Tissue/cell level

Tissue: peripheral nerve sheath.
Cell: Schwann cell. (chiassonmackenzie2023cellularmechanismsof pages 1-2)

8. Temporal development

8.1 Onset

Clinical presentation can occur with vestibular schwannomas (NF2-related) or with painful peripheral/spinal schwannomas (non-NF2 forms). (evans2025historyandclinical pages 1-2, hino2025optimaldeliveryof pages 1-2)

8.2 Progression/course

NF2-SWN is associated with progressive morbidities and monitored longitudinally by imaging/audiometry/neurologic deficits. (freier2024theimpactof pages 1-2)
Tumor growth rates and clinical impact can be highly variable; pain does not reliably track burden. (chiassonmackenzie2023cellularmechanismsof pages 1-2)

9. Inheritance and population

9.1 Epidemiology (recent statistics)

NF2-related schwannomatosis prevalence (England): - Manchester highly ascertained diagnostic prevalence 1 in 50,500 and calculated birth prevalence 1 in 27,956; an “updated prevalence across England in 2024…at least 1 in 58,000.” (Evans et al., 2025; Familial Cancer) (evans2025historyandclinical pages 1-2)

Schwannomatosis and gene-specific prevalence estimates (UK; 2024 cohort paper background): - NF2-related SWN prevalence ~1 in 61,332 (UK data). (smith2024geneticfindingsin pages 1-5) - Non-NF2 schwannomatosis ~1 in 103,700; germline LZTR1 ~1 in 527,000; germline SMARCB1 ~1 in 1.1 million. (smith2024geneticfindingsin pages 1-5)

Population schwannoma risk: - “Over one in 500 people in the general population may develop a schwannoma during their lifetime.” (Smith et al., 2024) (smith2024geneticfindingsin pages 1-5)

9.2 Inheritance patterns

NF2-SWN: autosomal dominant (complete penetrance noted in NF2-SWN context). (freier2024theimpactof pages 1-2)
LZTR1-SWN: autosomal dominant with incomplete penetrance. (perrino2025updateoncancer pages 5-7)
SMARCB1-SWN: familial tumor predisposition; specific penetrance estimates not extracted from retrieved pages. (perrino2025updateoncancer pages 5-7)

10. Diagnostics

10.1 Clinical criteria and modern classification (2022+)

Diagnostic criteria have evolved and now integrate molecular findings; 2019 Manchester revisions introduced molecular criteria and 2022 international committee updated terminology and criteria. (tamura2024historicaldevelopmentof pages 1-3)

Mosaicism definition (key diagnostic concept): - Mosaicism can be defined by “clearly <50%” allele fraction in blood/saliva or by a pathogenic NF2 variant found in ≥2 anatomically unrelated tumors but absent from unaffected tissue. (tamura2024historicaldevelopmentof pages 3-4)

10.2 Genetic testing strategy (real-world implementation)

Tumor-inclusive testing improves yield: blood-only 25% vs 36% with tumor analysis; mosaic NF2 often requires testing two tumors. (smith2024geneticfindingsin pages 1-5)
Deep NGS and adequate neoplastic content (≥20%) improve somatic detection. (smith2024geneticfindingsin pages 1-5)

Practical interpretation: for patients with multiple schwannomas not meeting classic NF2 clinical criteria, a modern workflow commonly requires paired tumor sequencing and high-depth methods to detect low-level mosaic NF2, alongside germline SMARCB1/LZTR1 testing. (smith2024geneticfindingsin pages 1-5)

10.3 Imaging / monitoring

NF2-SWN progression monitoring includes neurologic deficits, neuroimaging, speech and pure-tone audiometry. (freier2024theimpactof pages 1-2)

10.4 Differential diagnosis

Not systematically extracted from the retrieved evidence set; however, misclassification risks exist (e.g., overlap between NF2-related and non-NF2 schwannomatosis; need for genetic testing). (smith2024geneticfindingsin pages 1-5)

11. Outcome / prognosis

11.1 Survival and life expectancy

A recent management review states that “life expectancy…is nearly normal” in schwannomatosis, while acknowledging malignant transformation risk. (nagasaka2025geneticbasisand pages 1-2)

11.2 Morbidity

Major morbidity drivers include chronic pain and neurologic deficits (hearing loss, facial weakness, balance issues). (freier2024theimpactof pages 1-2, hino2025optimaldeliveryof pages 1-2)

12. Treatment

12.1 Current applications and real-world implementations

Surgical management (standard of care for symptomatic tumors)

Symptomatic lesion surgery is frequently used; however, persistent/recurrent pain may occur due to nerve injury or recurrence; multifocal disease may require repeated operations (average 3.4 surgical procedures in 10 years reported in a pain-management review). (hino2025optimaldeliveryof pages 4-6)

MAXO suggestions: tumor resection; nerve sheath tumor excision; decompression surgery.

Symptom-based pharmacotherapy for pain

Commonly used agents include gabapentin/pregabalin, NSAIDs, tricyclic antidepressants (e.g., amitriptyline), SNRIs (e.g., duloxetine), anticonvulsants, and short-acting opioids. (hino2025optimaldeliveryof pages 1-2)

MAXO suggestions: analgesic therapy; neuropathic pain pharmacotherapy.

Neuromodulation

Scrambler therapy (transcutaneous stimulation) is described as a noninvasive neuromodulation option in schwannomatosis pain management. (hino2025optimaldeliveryof pages 2-4)

MAXO suggestions: neuromodulation therapy; transcutaneous electrical stimulation.

12.2 Targeted/advanced therapeutics and experimental trials (2023–2026 registry data)

Pain-focused trials (primarily non-NF2 schwannomatosis)

1) STARFISH — NCT05684692 (ClinicalTrials.gov; first posted 2023-01-13; recruiting as of 2026-04-23) - Trial description: “placebo-controlled, multi-arm phase II platform screening trial” for “moderate-to-severe pain due to schwannomatosis.” (NCT05684692 chunk 1) - Agents: siltuximab (anti-IL-6) and erenumab-aooe (CGRP receptor antibody) embedded sub-studies. (NCT05684692 chunk 1)

2) Tanezumab — NCT04163419 (ClinicalTrials.gov; last update posted 2024-03-13) - Direct quote (pain prevalence): “68% experiencing chronic pain.” (NCT04163419 chunk 1) - Primary endpoint: change in worst pain from baseline to week 8 by NRS-11. (NCT04163419 chunk 1) - Design: randomized, double-blind, placebo-controlled; enrollment 9; 40-week total duration including 24-week safety follow-up. (NCT04163419 chunk 1)

Tumor-directed targeted therapy trials in NF2-related schwannomatosis

INTUITT-NF2 — NCT04374305 (ClinicalTrials.gov; first posted 2020-05-05; recruiting as of 2026-05-06) - Master study: multi-arm phase II platform/basket trial for NF2-SWN tumors (vestibular and non-vestibular schwannomas, meningiomas, ependymomas). (NCT04374305 chunk 1) - Sub-studies include brigatinib, neratinib, and retifanlimab + bevacizumab. (NCT04374305 chunk 1) - Primary on-study evaluation includes radiographic response rate used for interim analyses and arm selection/expansion. (NCT04374305 chunk 1)

12.3 Expert opinion / authoritative analysis

Tamura et al. emphasize that repeated revisions and molecular criteria can make NF2 diagnostic criteria confusing in practice, motivating clinician-facing reviews and highlighting the shift to gene-based schwannomatosis terminology. (tamura2024historicaldevelopmentof pages 1-3)
Smith et al. conclude “the importance of comprehensive genetic testing” and variant classification, supported by mosaic NF2 detection via tumor testing. (smith2024geneticfindingsin pages 1-5)

13. Prevention

No primary prevention strategies are established because schwannomatosis is genetic; prevention focuses on secondary prevention (early detection, surveillance) and tertiary prevention (preventing complications and disability). Surveillance recommendations are referenced in the pediatric surveillance perspective, but detailed schedules were not extractable from the pages retrieved in this run. (perrino2025updateoncancer pages 5-7)

14. Other species / natural disease

No naturally occurring schwannomatosis analogs in non-human species were identified in the retrieved evidence set. (evidence gap)

15. Model organisms

15.1 Experimental models (NF2-mutant schwannoma)

Mouse models and primary mouse Schwann cells are used to study NF2-loss schwannoma heterogeneity and signaling programs. (chiassonmackenzie2023cellularmechanismsof pages 1-2)

15.2 Utility and limitations (from retrieved sources)

NF2-mutant schwannomas are genetically “cold” with few cooperating mutations, yet highly heterogeneous—these models support study of heterogeneity mechanisms and biomarker development. (chiassonmackenzie2023cellularmechanismsof pages 1-2)

Structured summary table (for knowledge base ingestion)

Category	Item	Key details	Recent source / year	URL	Evidence
Disease identifier	Schwannomatosis	Umbrella term adopted in 2022; gene-based subtypes include NF2-related schwannomatosis, SMARCB1-related schwannomatosis, LZTR1-related schwannomatosis, 22q-related schwannomatosis, SWN-NOS, SWN-NEC	Nagasaka & Phi, 2025	https://doi.org/10.3340/jkns.2025.0001	(nagasaka2025geneticbasisand pages 1-2)
Disease identifier	MONDO	MONDO:0008075 schwannomatosis; related entries include MONDO:0007039 NF2-related schwannomatosis, MONDO:0024517 SMARCB1-related schwannomatosis, MONDO:0014299 LZTR1-related schwannomatosis	Open Targets / MONDO context, accessed via current evidence	https://platform.opentargets.org	(OpenTargets Search: Schwannomatosis)
Modern definition	NF2-related schwannomatosis	Formerly “neurofibromatosis type 2”; renamed because neurofibromas are not a defining feature; classically characterized by bilateral vestibular schwannomas with additional meningiomas/ependymomas/schwannomas	Tamura et al., 2024; Rai et al., 2025	https://doi.org/10.2176/jns-nmc.2024-0067 ; https://doi.org/10.1177/19714009251313510	(tamura2024historicaldevelopmentof pages 1-3, rai2025classificationofschwannomas pages 1-2)
Subtype	NF2-related schwannomatosis	Gene: NF2; autosomal dominant; high penetrance/near-certain disease with constitutional pathogenic variant; mosaic disease common, especially de novo cases	Nagasaka & Phi, 2025; Perrino et al., 2025	https://doi.org/10.3340/jkns.2025.0001 ; https://doi.org/10.1158/1078-0432.ccr-24-3278	(nagasaka2025geneticbasisand pages 1-2, perrino2025updateoncancer pages 5-7)
Subtype	SMARCB1-related schwannomatosis	Gene: SMARCB1; autosomal dominant familial tumor predisposition; typically peripheral/spinal schwannomas, no bilateral vestibular schwannomas; meningioma and MPNST risk reported	Perrino et al., 2025	https://doi.org/10.1158/1078-0432.ccr-24-3278	(perrino2025updateoncancer pages 5-7)
Subtype	LZTR1-related schwannomatosis	Gene: LZTR1; autosomal dominant with incomplete penetrance; peripheral schwannomas predominate; unilateral vestibular schwannoma can occur	Perrino et al., 2025; Uliana et al., 2024	https://doi.org/10.1158/1078-0432.ccr-24-3278 ; https://doi.org/10.3390/genes15070916	(perrino2025updateoncancer pages 5-7)
Major genes	Core causal genes	Principal disease genes across schwannomatosis are NF2, SMARCB1, LZTR1	Open Targets association summary; multiple reviews	https://platform.opentargets.org	(OpenTargets Search: Schwannomatosis)
Pathogenesis	Non-NF2 three-/four-hit model	For SMARCB1/LZTR1-related disease: germline variant retained in tumor, chromosome 22 loss/LOH removes wild-type allele, followed by somatic NF2 alteration in tumor	Nagasaka & Phi, 2025; Tamura et al., 2024	https://doi.org/10.3340/jkns.2025.0001 ; https://doi.org/10.2176/jns-nmc.2024-0067	(nagasaka2025geneticbasisand pages 1-2, tamura2024historicaldevelopmentof pages 3-4)
Hallmark clinical features	Pain	Chronic pain is a major hallmark, often poorly correlated with tumor size/location/burden; symptom-based multidisciplinary pain management is emphasized	Nagasaka & Phi, 2025; Hino et al., 2025	https://doi.org/10.3340/jkns.2025.0001 ; https://doi.org/10.2147/tcrm.s362794	(nagasaka2025geneticbasisand pages 1-2, hino2025optimaldeliveryof pages 2-4)
Hallmark clinical features	NF2-related phenotype	Bilateral vestibular schwannomas, other cranial/spinal schwannomas, intradermal schwannomas, meningiomas, less commonly ependymomas; may also present with unilateral VS plus other tumors	Perrino et al., 2025; Evans et al., 2025	https://doi.org/10.1158/1078-0432.ccr-24-3278 ; https://doi.org/10.1007/s10689-025-00504-5	(perrino2025updateoncancer pages 5-7, evans2025historyandclinical pages 1-2)
Hallmark clinical features	SMARCB1/LZTR1 phenotype	Usually multiple non-vestibular schwannomas affecting peripheral and spinal nerves; painful tumors common; bilateral VS generally absent in SMARCB1-related disease	Tamura et al., 2024; Perrino et al., 2025	https://doi.org/10.2176/jns-nmc.2024-0067 ; https://doi.org/10.1158/1078-0432.ccr-24-3278	(tamura2024historicaldevelopmentof pages 3-4, perrino2025updateoncancer pages 5-7)
Diagnostic criteria	NF2-related schwannomatosis	Diagnosis can be made by bilateral VS, or identical NF2 pathogenic variant in ≥2 anatomically distinct NF2-related tumors, or major/minor criteria combinations; molecular criteria formally incorporated in recent revisions	Tamura et al., 2024; Rai et al., 2025	https://doi.org/10.2176/jns-nmc.2024-0067 ; https://doi.org/10.1177/19714009251313510	(tamura2024historicaldevelopmentof pages 3-4, rai2025classificationofschwannomas pages 1-2)
Diagnostic testing	Mosaicism and tumor testing	Mosaicism may be inferred by blood/saliva variant allele fraction <50% or shared pathogenic variant across ≥2 anatomically unrelated tumors; tumor analysis materially improves diagnostic yield	Tamura et al., 2024; Smith et al., 2024	https://doi.org/10.2176/jns-nmc.2024-0067 ; https://doi.org/10.1136/jmg-2024-110217	(tamura2024historicaldevelopmentof pages 3-4, smith2024geneticfindingsin pages 1-5)
Diagnostic yield	Blood vs tumor-inclusive testing	In a 154-person cohort with non-vestibular schwannoma(s), overall molecular diagnosis was 25% using blood alone and 36% when tumor analysis was included; 18/19 NF2 findings were mosaic, with 17 detected only when 2 tumors were tested	Smith et al., 2024	https://doi.org/10.1136/jmg-2024-110217	(smith2024geneticfindingsin pages 1-5)
Epidemiology	Lifetime schwannoma risk	Lifetime risk of schwannoma estimated >1/500; about 75% are vestibular schwannomas	Smith et al., 2024	https://doi.org/10.1136/jmg-2024-110217	(smith2024geneticfindingsin pages 1-5)
Epidemiology	NF2-related prevalence	Diagnostic prevalence in Manchester reported 1 in 50,500; birth prevalence 1 in 27,956; updated England prevalence in 2024 at least 1 in 58,000	Evans et al., 2025	https://doi.org/10.1007/s10689-025-00504-5	(evans2025historyandclinical pages 1-2)
Epidemiology	Non-NF2 and gene-specific prevalence	UK prevalence estimates: non-NF2 schwannomatosis 1 in 103,700; germline LZTR1 variant-related disease 1 in 527,000; germline SMARCB1 variant-related disease 1.1 million	Smith et al., 2024	https://doi.org/10.1136/jmg-2024-110217	(smith2024geneticfindingsin pages 1-5)
Quality of life	NF2-SWN mental health burden	In 77 surveyed NF2-SWN patients, clinically relevant symptoms: depression 30%, anxiety 16%, somatic burden 32%; QoL correlated with physician-rated severity (r=0.614)	Freier et al., 2024	https://doi.org/10.1038/s41598-024-57401-7	(freier2024theimpactof pages 1-2)
Quality of life	Specific NF2-SWN QoL impacts	In the same cohort, 75% (58/77) reported disease negatively affected outlook on life and 66% (51/77) reported hearing problems affecting activities	Freier et al., 2024	https://doi.org/10.1038/s41598-024-57401-7	(freier2024theimpactof pages 3-4)
Current management	Standard care	Surgical resection for symptomatic/accessible lesions; radiotherapy and bevacizumab used mainly in NF2-related disease; supportive multidisciplinary pain care central	Nagasaka & Phi, 2025	https://doi.org/10.3340/jkns.2025.0001	(nagasaka2025geneticbasisand pages 1-2)
Active trial	NCT05684692 STARFISH	Schwannomatosis pain platform trial; interventions: siltuximab and erenumab-aooe vs placebo; primary endpoint: change in worst pain intensity (NRS-11) from baseline to Day 85; status Recruiting	ClinicalTrials.gov record, 2023	https://clinicaltrials.gov/study/NCT05684692	(NCT05684692 chunk 2, NCT05684692 chunk 1)
Active trial	NCT04163419 Tanezumab	Phase 2 randomized placebo-controlled trial for moderate to severe pain due to schwannomatosis; intervention tanezumab; primary endpoint: change in worst pain (NRS-11) at Week 8; enrollment 9; status listed Unknown / last known active-not-recruiting	ClinicalTrials.gov record, 2020	https://clinicaltrials.gov/study/NCT04163419	(NCT04163419 chunk 1, NCT04163419 chunk 2)
Active trial	NCT04374305 INTUITT-NF2	Phase 2 platform trial for NF2-related schwannomatosis tumors; interventions: brigatinib, neratinib, retifanlimab + bevacizumab; primary on-study evaluation includes radiographic response rate; status Recruiting	ClinicalTrials.gov record, 2020	https://clinicaltrials.gov/study/NCT04374305	(NCT04374305 chunk 1)
Trial landscape note	Pain vs tumor-directed trials	Current active interventional landscape separates pain-focused trials (STARFISH, tanezumab) from tumor-directed NF2 trials (INTUITT-NF2); pain trials are mainly in non-NF2 schwannomatosis, whereas INTUITT targets NF2-related tumor burden	ClinicalTrials.gov records and review synthesis	https://clinicaltrials.gov	(NCT05684692 chunk 1, NCT04163419 chunk 1, NCT04374305 chunk 1, hino2025optimaldeliveryof pages 2-4)

Table: This table condenses current schwannomatosis nomenclature, genetics, clinical features, epidemiology, diagnostics, and actively recruiting or recent interventional trials. It is designed as a quick-reference artifact for disease knowledge base curation and evidence tracking.

Notes on evidence gaps and recommended curation add-ons

1) OMIM/Orphanet/ICD/MeSH identifiers were not directly retrievable in this tool run; add via direct database lookups. 2) Non-NF2 schwannomatosis natural history, penetrance estimates by variant class, and malignant transformation rates require additional primary cohort studies and guidelines not fully accessible here. 3) Environmental/lifestyle modifiers were not identified in the accessed evidence.

Key URLs (access points in this run)

Tamura et al., 2024-06-19 (online): https://doi.org/10.2176/jns-nmc.2024-0067 (tamura2024historicaldevelopmentof pages 1-3)
Smith et al., 2024-08: https://doi.org/10.1136/jmg-2024-110217 (smith2024geneticfindingsin pages 1-5)
Freier et al., 2024-03: https://doi.org/10.1038/s41598-024-57401-7 (freier2024theimpactof pages 1-2)
Chiasson‑MacKenzie et al., 2023-03: https://doi.org/10.1038/s41467-023-37226-0 (chiassonmackenzie2023cellularmechanismsof pages 1-2)
STARFISH (NCT05684692): https://clinicaltrials.gov/study/NCT05684692 (NCT05684692 chunk 1)
Tanezumab pain trial (NCT04163419): https://clinicaltrials.gov/study/NCT04163419 (NCT04163419 chunk 1)
INTUITT-NF2 (NCT04374305): https://clinicaltrials.gov/study/NCT04374305 (NCT04374305 chunk 1)

References

(OpenTargets Search: Schwannomatosis): Open Targets Query (Schwannomatosis, 10 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(tamura2024historicaldevelopmentof pages 1-3): Ryota TAMURA, Masahiro YO, and Masahiro TODA. Historical development of diagnostic criteria for nf2-related schwannomatosis. Neurologia medico-chirurgica, 64:299-308, Aug 2024. URL: https://doi.org/10.2176/jns-nmc.2024-0067, doi:10.2176/jns-nmc.2024-0067. This article has 12 citations and is from a peer-reviewed journal.
(nagasaka2025geneticbasisand pages 1-2): Shohei Nagasaka and Ji Hoon Phi. Genetic basis and clinical management of schwannomatosis. Journal of Korean Neurosurgical Society, 68:286-293, May 2025. URL: https://doi.org/10.3340/jkns.2025.0001, doi:10.3340/jkns.2025.0001. This article has 1 citations and is from a peer-reviewed journal.
(rai2025classificationofschwannomas pages 1-2): Pranjal Rai, Girish Bathla, Neetu Soni, Amit Desai, Dinesh Rao, Prasanna Vibhute, and Amit Agarwal. Classification of schwannomas and the new naming convention for "neurofibromatosis-2": genetic updates and international consensus recommendation. The neuroradiology journal, pages 19714009251313510, Jan 2025. URL: https://doi.org/10.1177/19714009251313510, doi:10.1177/19714009251313510. This article has 7 citations and is from a peer-reviewed journal.
(evans2025historyandclinical pages 1-2): D. Gareth Evans, Jaishri O. Blakeley, and Scott R. Plotkin. History and clinical epidemiology of nf2-related schwannomatosis. Familial Cancer, Oct 2025. URL: https://doi.org/10.1007/s10689-025-00504-5, doi:10.1007/s10689-025-00504-5. This article has 2 citations and is from a peer-reviewed journal.
(chiassonmackenzie2023cellularmechanismsof pages 1-2): Christine Chiasson-MacKenzie, Jeremie Vitte, Ching-Hui Liu, Emily A. Wright, Elizabeth A. Flynn, Shannon L. Stott, Marco Giovannini, and Andrea I. McClatchey. Cellular mechanisms of heterogeneity in nf2-mutant schwannoma. Nature Communications, Mar 2023. URL: https://doi.org/10.1038/s41467-023-37226-0, doi:10.1038/s41467-023-37226-0. This article has 26 citations and is from a highest quality peer-reviewed journal.
(perrino2025updateoncancer pages 5-7): Melissa R. Perrino, Marjolijn C. J. Jongmans, Gail E. Tomlinson, Mary-Louise C. Greer, Sarah R. Scollon, Sarah G. Mitchell, Jordan R. Hansford, Kris Ann P. Schultz, Wendy K. Kohlmann, Jennifer M. Kalish, Suzanne P. MacFarland, Anirban Das, Kara N. Maxwell, Stefan M. Pfister, Rosanna Weksberg, Orli Michaeli, Uri Tabori, Gina M. Ney, Philip J. Lupo, Jack J. Brzezinski, Douglas R. Stewart, Emma R. Woodward, and Christian P. Kratz. Update on cancer and central nervous system tumor surveillance in pediatric nf2-, smarcb1-, and lztr1-related schwannomatosis. Clinical cancer research : an official journal of the American Association for Cancer Research, Feb 2025. URL: https://doi.org/10.1158/1078-0432.ccr-24-3278, doi:10.1158/1078-0432.ccr-24-3278. This article has 8 citations.
(smith2024geneticfindingsin pages 1-5): Miriam J Smith, Cristina Perez-Becerril, Mwee van der Meer, George J Burghel, Sarah J Waller, Megan Carney, Sancha Bunstone, Katherine Fryer, Naomi L Bowers, Claire L Hartley, Philip T Smith, Scott A Rutherford, Simon R Freeman, Simon K W Lloyd, Omar N Pathmanaban, Andrew Thomas King, Dorothy Halliday, Chris Duff, and D Gareth Evans. Genetic findings in people with schwannomas who do not meet clinical diagnostic criteria for nf2-related schwannomatosis. Journal of Medical Genetics, 61:1011-1015, Aug 2024. URL: https://doi.org/10.1136/jmg-2024-110217, doi:10.1136/jmg-2024-110217. This article has 5 citations and is from a domain leading peer-reviewed journal.
(NCT05684692 chunk 1): Scott R. Plotkin, MD, PhD. Screening Trial for Pain Relief in Schwannomatosis (STARFISH). Massachusetts General Hospital. 2023. ClinicalTrials.gov Identifier: NCT05684692
(NCT04163419 chunk 1): Scott R. Plotkin, MD, PhD. Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis. Massachusetts General Hospital. 2020. ClinicalTrials.gov Identifier: NCT04163419
(NCT04374305 chunk 1): Scott R. Plotkin, MD, PhD. Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2). Scott R. Plotkin, MD, PhD. 2020. ClinicalTrials.gov Identifier: NCT04374305
(tamura2024historicaldevelopmentof pages 3-4): Ryota TAMURA, Masahiro YO, and Masahiro TODA. Historical development of diagnostic criteria for nf2-related schwannomatosis. Neurologia medico-chirurgica, 64:299-308, Aug 2024. URL: https://doi.org/10.2176/jns-nmc.2024-0067, doi:10.2176/jns-nmc.2024-0067. This article has 12 citations and is from a peer-reviewed journal.
(freier2024theimpactof pages 3-4): Anna Freier, Anna C. Lawson McLean, Denise Loeschner, Steffen K. Rosahl, and Johannes Kruse. The impact of mental health on health-related quality of life in patients with nf2-related schwannomatosis. Scientific Reports, Mar 2024. URL: https://doi.org/10.1038/s41598-024-57401-7, doi:10.1038/s41598-024-57401-7. This article has 6 citations and is from a peer-reviewed journal.
(freier2024theimpactof pages 1-2): Anna Freier, Anna C. Lawson McLean, Denise Loeschner, Steffen K. Rosahl, and Johannes Kruse. The impact of mental health on health-related quality of life in patients with nf2-related schwannomatosis. Scientific Reports, Mar 2024. URL: https://doi.org/10.1038/s41598-024-57401-7, doi:10.1038/s41598-024-57401-7. This article has 6 citations and is from a peer-reviewed journal.
(hino2025optimaldeliveryof pages 1-2): Utaro Hino, Ryota Tamura, and Masahiro Toda. Optimal delivery of pain management in schwannomatosis: a literature review. Therapeutics and Clinical Risk Management, 21:61-68, Jan 2025. URL: https://doi.org/10.2147/tcrm.s362794, doi:10.2147/tcrm.s362794. This article has 2 citations and is from a peer-reviewed journal.
(madison2026schwannomatosistumormodeling pages 1-2): Mackenzie S. Madison, Huazhen Xu, Yarelis Gonzalez-Vargas, Marybeth G. Yonk, Charee M. Thompson, Hurley Haney, Danielle Babbitt, Yuhong Du, Angela C. Hirbe, Nicholas M. Boulis, Ren-Yuan Bai, and Kecheng Lei. Schwannomatosis tumor modeling: progress and prospects for translational research. Journal of Biological Engineering, Feb 2026. URL: https://doi.org/10.1186/s13036-026-00634-z, doi:10.1186/s13036-026-00634-z. This article has 0 citations and is from a peer-reviewed journal.
(freier2024theimpactof pages 2-3): Anna Freier, Anna C. Lawson McLean, Denise Loeschner, Steffen K. Rosahl, and Johannes Kruse. The impact of mental health on health-related quality of life in patients with nf2-related schwannomatosis. Scientific Reports, Mar 2024. URL: https://doi.org/10.1038/s41598-024-57401-7, doi:10.1038/s41598-024-57401-7. This article has 6 citations and is from a peer-reviewed journal.
(otaner2026vestibularschwannomagenetic pages 2-4): Franciska Otaner, Vratko Himic, Luis O. Vargas, Matthew Abikenari, Neelesh Pandey, Shayndhan Sivanathan, Olivia Kalmanson, Aparna Govindan, Diane Jung, Dagoberto Estevez-Ordonez, Amy Wang, Sanjeeva Jeyaretna, Ashish H. Shah, Ricardo J. Komotar, Bradley Gampel, Christine Dinh, and Michael E. Ivan. Vestibular schwannoma: genetic and epigenetic mechanisms, hearing loss, and emerging therapies. Journal of Neuro-Oncology, May 2026. URL: https://doi.org/10.1007/s11060-026-05621-4, doi:10.1007/s11060-026-05621-4. This article has 0 citations and is from a peer-reviewed journal.
(hino2025optimaldeliveryof pages 4-6): Utaro Hino, Ryota Tamura, and Masahiro Toda. Optimal delivery of pain management in schwannomatosis: a literature review. Therapeutics and Clinical Risk Management, 21:61-68, Jan 2025. URL: https://doi.org/10.2147/tcrm.s362794, doi:10.2147/tcrm.s362794. This article has 2 citations and is from a peer-reviewed journal.
(hino2025optimaldeliveryof pages 2-4): Utaro Hino, Ryota Tamura, and Masahiro Toda. Optimal delivery of pain management in schwannomatosis: a literature review. Therapeutics and Clinical Risk Management, 21:61-68, Jan 2025. URL: https://doi.org/10.2147/tcrm.s362794, doi:10.2147/tcrm.s362794. This article has 2 citations and is from a peer-reviewed journal.
(NCT05684692 chunk 2): Scott R. Plotkin, MD, PhD. Screening Trial for Pain Relief in Schwannomatosis (STARFISH). Massachusetts General Hospital. 2023. ClinicalTrials.gov Identifier: NCT05684692
(NCT04163419 chunk 2): Scott R. Plotkin, MD, PhD. Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis. Massachusetts General Hospital. 2020. ClinicalTrials.gov Identifier: NCT04163419

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Schwannomatosis — Comprehensive Disease Characteristics Report (Neoplastic)

Target Disease

Executive summary (current understanding)

1. Disease information

1.1 What is the disease?

1.2 Key identifiers

1.3 Synonyms / alternative names

1.4 Evidence source type

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

Genetic risk factors

Environmental risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes

3.1 Core phenotype domains and suggested HPO terms

3.2 Age of onset and progression

3.3 Frequency / statistics for selected phenotypes

Pain frequency

NF2-related QoL and mental health statistics (2024 peer-reviewed)

3.4 Quality of life impact

4. Genetic / molecular information

4.1 Causal genes (major)

4.2 Pathogenic variants and variant spectrum (from retrieved evidence)

4.3 Inheritance and penetrance

4.4 Multi-hit / tumorigenesis models

4.5 Epigenetic information

5. Environmental information

6. Mechanism / pathophysiology

6.1 Causal chain (genotype → cell biology → tumors and symptoms)

6.2 Key pathways (examples) and GO term suggestions

6.3 Cell types and CL term suggestions

6.4 Mechanistic models and experimental systems (model organism evidence)

7. Anatomical structures affected

7.1 Organ/system level

7.2 Tissue/cell level

8. Temporal development

8.1 Onset

8.2 Progression/course

9. Inheritance and population

9.1 Epidemiology (recent statistics)

9.2 Inheritance patterns

10. Diagnostics

10.1 Clinical criteria and modern classification (2022+)

10.2 Genetic testing strategy (real-world implementation)

10.3 Imaging / monitoring